| Autor: |
Lim CJM; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK., Bray J; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK., Janhunen SK; Organon R&D Finland, Itäinen Pitkäkatu 4, 20520 Turku, Finland., Platt B; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK., Riedel G; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK. |
| Jazyk: |
angličtina |
| Zdroj: |
Biomolecules [Biomolecules] 2024 Aug 15; Vol. 14 (8). Date of Electronic Publication: 2024 Aug 15. |
| DOI: |
10.3390/biom14081008 |
| Abstrakt: |
One aspect of reproducibility in preclinical research that is frequently overlooked is the physical condition in which physiological, pharmacological, or behavioural recordings are conducted. In this study, the physical conditions of mice were altered through the attachments of wireless electrophysiological recording devices (Neural Activity Tracker-1, NAT-1). NAT-1 devices are miniaturised multichannel devices with onboard memory for direct high-resolution recording of brain activity for >48 h. Such devices may limit the mobility of animals and affect their behavioural performance due to the added weight (total weight of approximately 3.4 g). The mice were additionally treated with saline (control), N-methyl-D-aspartate (NMDA) receptor antagonist MK801 (0.85 mg/kg), or the muscarinic acetylcholine receptor blocker scopolamine (0.65 mg/kg) to allow exploration of the effect of NAT-1 attachments in pharmacologically treated mice. We found only minimal differences in behavioural outcomes with NAT-1 attachments in standard parameters of locomotor activity widely reported for the open field test between the drug treatments. Hypoactivity was globally observed as a consistent outcome in the MK801-treated mice and hyperactivity in scopolamine groups regardless of NAT-1 attachments. These data collectively confirm the reproducibility for combined behavioural, pharmacological, and physiological endpoints even in the presence of lightweight wireless data loggers. The NAT-1 therefore constitutes a pertinent tool for investigating brain activity in, e.g., drug discovery and models of neuropsychiatric and/or neurodegenerative diseases with minimal effects on pharmacological and behavioural outcomes. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
